A Phase 2b Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis
Brief description of study
The purpose of this study is to see if an experimental drug called MK-3655 helps people with a liver disease called nonalcoholic steatohepatitis (NASH). “Experimental” means MK-3655 has not been approved for commercial use by the US Food and Drug Administration. This study will test MK-3655 against placebo. A placebo looks like a study drug, but it has no active ingredients. This study will test the safety of MK-3655 compared to placebo and how well MK-3655 works and is tolerated compared to the placebo.
Clinical Study Identifier: s20-00337
ClinicalTrials.gov Identifier: NCT04583423
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
